Table 2 Demographic characteristics and baseline details of the study participants
Study group | Group 1 (4 mg/kg) n = 18 | Group 2 (8 mg/kg) n = 19 | P-value |
|---|---|---|---|
Gender [% female (n)] | 61.1 (11) | 57.9 (11) | 1.0 |
Race [% white (n)] | 88.9 (16) | 79.0 (15) | 0.11 |
Race [%Asian (n)] | 0.0 (0) | 10.5 (2) | |
Race [% Hispanic or Latin (n)] | 11.1 (2) | 0.0 (0) | |
Race [% African American (n)] | 0.0 (0) | 10.5 (2) | |
Age (mean years ± SD) | 43 ± 16.52 (18 – 68) | 41 ± 18.0 (19 – 85) | 0.79 |
Visual acuity (mean ± SD) | 34.28 ± 15.39 | 41.11 ± 14.98 | 0.18 |
Vitreous haze (mean ± SD) | 1.25 ± 0.82 | 1.5 ± 0.95 | 0.48 |
Central macular thickness (mean ± SD) | 411.97 ± 215.43 | 308.76 ± 91.03 | 0.08 |
Lens status (% pseudophakic) | 27.8 (5) | 15.8 (3) | 0.45 |
Treatment Naïve (%) | 55.5 (10) | 63.1 (12) | 0.74 |
Systemic corticosteroid use (%(n)) | 27.8 (5) | 21.1 (3) | 0.45 |
Corticosteroid dose (mean ± SD) | 18.0 ± 12.5 | 20.0 ± 14.1 | 0.86 |
Prior IMT use (%(n)) | 22.2 (4) | 26.3 (5) | 1.0 |
Disease Type [% (n)] | |||
Intermediate | 16.7 (3) | 15.8 (3) | 0.30 |
Posterior | 22.2 (4) | 5.3 (1) | |
Panuveitis | 61.1 (11) | 78.9 (15) | |
Disease category [% (n)] | |||
Active uveitis with no treatment | 55.6 (10) | 68.4 (13) | 0.51 |
Active uveitis with treatment | 44.4 (8) | 31.6 (6) | |
Underlying disease [% (n)] | |||
Sarcoidosis | 5.6 (1) | 5.3 (1) | 0.27 |
Vogt-Koyangi-Harada Syndrome | 10.5 (2) | ||
Birdshot choroidopathy | 11.1 (2) | ||
Punctate inner choroiditis | 5.6 (1) | ||
Bechet disease | 5.6 (1) | ||
Tubulointerstitial nephritis and uveitis (TINU syndrome) | 5.6 (1) | ||
Idiopathic | 66.7 (12) | 84.2 (16) | |